Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21449911
Doll C, et al. (2011) Agonist-selective patterns of ยต-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br J Pharmacol 164, 298-307 21449911
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S363-p - MOR-1 (mouse)
Modsite: STIEQQNsARIRQNt SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): S365‑p, MOR‑1 iso5 (human): S365‑p, MOR‑1 (mouse): S363‑p, MOR‑1 (rat): S363‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DAMGO no change compared to control

T370-p - MOR-1 (mouse)
Modsite: sARIRQNtREHPstA SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): T372‑p, MOR‑1 iso5 (human): T372‑p, MOR‑1 (mouse): T370‑p, MOR‑1 (rat): T370‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DAMGO increase
etonitazene increase
PKCA (human) increase
phorbol_ester increase
naloxone etonitazene inhibit treatment-induced increase Naloxone washout
morphine no change compared to control
NKH_477 no change compared to control
ConA no change compared to control
Downstream Regulation
Effect of modification (function):  receptor desensitization, induced

S375-p - MOR-1 (mouse)
Modsite: QNtREHPstANtVDR SwissProt Entrez-Gene
Orthologous residues
MOR‑1 (human): S377‑p, MOR‑1 iso5 (human): S377‑p, MOR‑1 (mouse): S375‑p, MOR‑1 (rat): S375‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
Relevant cell lines - cell types - tissues:  293 (epithelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
DAMGO increase
etonitazene increase
morphine increase
naloxone etonitazene inhibit treatment-induced increase Naloxone washout
phorbol_ester no change compared to control
NKH_477 no change compared to control
ConA no change compared to control
Downstream Regulation
Effect of modification (function):  phosphorylation, receptor desensitization, induced
Comments:  induces phosphorylation at T370